liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin
Linköpings universitet, Institutionen för medicin och hälsa, Internmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Medicincentrum, Endokrin- och magtarmmedicinska kliniken US.
2010 (engelsk)Inngår i: NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, ISSN 0939-4753, Vol. 20, nr 8, s. 553-557Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Recently two studies on the effect of addition of extended-release niacin to statin treatment on measures of carotid atherosclerosis were estimated in the ARBITER 6-HALTS study (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies) study and the Oxford Niacin Study were published. Adding niacin to statin treatment significantly diminished carotid atherosclerosis as measured by ultrasound carotid intima-media thickness or magnetic resonance imaging. An inhibitor of niacin induced flushing, laropiprant has been developed and demonstrated to considerably improve the tolerability of niacin therapy without impeding on its effect on lipoproteins. Still however clear evidence for the clinical benefit of long-term niacin treatment on cardiovascular morbidity and mortality is lacking. The development situation for ezetimibe is similar to that of niacin. Long-term interventional studies with hard endpoints of both therapies are ongoing. Also both drugs, when proven efficient and safe, are eagerly needed in the prevention of cardiovascular disease.

sted, utgiver, år, opplag, sider
Elsevier Science B.V. Amsterdam , 2010. Vol. 20, nr 8, s. 553-557
Emneord [en]
Cardiovascular disease, Diabetes, Ezetimibe, Laropiprant, Niacin, Prevention
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-65936DOI: 10.1016/j.numecd.2010.07.003ISI: 000286128900001OAI: oai:DiVA.org:liu-65936DiVA, id: diva2:400791
Tilgjengelig fra: 2011-02-28 Laget: 2011-02-28 Sist oppdatert: 2011-02-28

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Olsson, Anders G

Søk i DiVA

Av forfatter/redaktør
Olsson, Anders G
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 29 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf